Clinical Trials Logo

Pulmonary Neoplasm clinical trials

View clinical trials related to Pulmonary Neoplasm.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03827850 Terminated - Lung Cancer Clinical Trials

FGFR Inhibitor in FGFR Dysregulated Cancer

FIND
Start date: March 25, 2019
Phase: Phase 2
Study type: Interventional

In the FIND trial, Non Small Cell Lung Carcinoma (NSCLC) patients with Fibroblast Growth Factor Receptor (FGFR) genetic alteration will be treated with the selective FGFR1-4 inhibitor erdafitinib. Archival samples, fresh frozen tumor samples and blood for circulating tumor DNA (ctDNA) will be collected before treatment. Patients will be treated until disease progression or unacceptable toxicity. In case of progression, fresh frozen tumor biopsies and ctDNA analyses will be performed to assess resistance mechanisms. The primary objective of the trial is to analyze the efficacy of erdafitinib in NSCLC patients with FGFR genetic alterations. NSCLC patient number will be based on a statistical hypothesis aiming at increasing the response rate comparing to chemotherapy/immunotherapy after standard treatment.